Vyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955PUBT·Aug 12 at 03:33 PMHIND-0.45%
Vyome | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.59 KEarnings Watch·May 29 at 07:44 AMHIND-0.45%
Vyome | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 31.59 KEarnings Watch·May 12 at 03:05 PMHIND-0.45%
Vyome | 10-K: FY2025 Revenue Beats Estimate at USD 319.71 KEarnings Watch·Apr 24 at 05:33 AMHIND-0.45%
Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan MarketTip Ranks·Apr 23 at 12:35 PMHIND-0.45%IBB-0.57%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·Mar 26 at 04:05 PMIXJ-0.88%XBI-0.75%
Cullen Investment Group LTD. Has $744,000 Holdings in Edwards Lifesciences Corporation $EWMarket Beat·Mar 26 at 03:30 AMHIND-0.45%FBT-0.11%
Sentynl and PRG partner for Progerinin licencePharmaceutical Technology·Mar 17 at 04:50 AMSBIO-1.24%ZYXIQ0.00%
Supriya Lifescience Publishes Postal Ballot Notice in NewspapersTip Ranks·Mar 11 at 04:53 PMRSLS0.00%LABU-2.57%
Vyome’s Livechain Acquires Humanyze to Expand AI HR AnalyticsTip Ranks·Feb 25 at 04:55 PMHIND-0.45%VYNE0.00%
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953TradingView·Feb 13 at 05:13 AMFBT-0.11%IBB-0.57%
